Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1967 2
1971 5
1972 1
1976 1
1977 1
1978 2
1979 1
1981 1
1982 2
1983 2
1984 2
1985 2
1986 3
1987 1
1988 1
1990 2
1992 2
1993 3
1995 1
1997 1
1998 2
1999 4
2000 9
2001 5
2002 5
2003 5
2004 2
2005 4
2006 15
2007 7
2008 8
2009 7
2010 18
2011 15
2012 20
2013 28
2014 25
2015 22
2016 25
2017 20
2018 29
2019 10
2020 13
2021 13
2022 17
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: tokunaga e. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. Among authors: tokunaga e. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Modi S, et al. Among authors: tokunaga e. N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825192 Free PMC article. Clinical Trial.
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V. Viale G, et al. Among authors: tokunaga e. ESMO Open. 2023 Aug;8(4):101615. doi: 10.1016/j.esmoop.2023.101615. Epub 2023 Aug 8. ESMO Open. 2023. PMID: 37562195 Free PMC article.
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz MP, Shimizu C, Huang CS, Lueck HJ, Beith J, Tokunaga E, Contreras JR, de Sant'Ana RO, Wei R, Shahir A, Nabinger SC, Forrester T, Johnston SRD, Harbeck N. Paluch-Shimon S, et al. Among authors: tokunaga e. Ther Adv Med Oncol. 2023 Feb 3;15:17588359231151840. doi: 10.1177/17588359231151840. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36756142 Free PMC article.
DNA replication stress and cancer chemotherapy.
Kitao H, Iimori M, Kataoka Y, Wakasa T, Tokunaga E, Saeki H, Oki E, Maehara Y. Kitao H, et al. Among authors: tokunaga e. Cancer Sci. 2018 Feb;109(2):264-271. doi: 10.1111/cas.13455. Epub 2017 Dec 22. Cancer Sci. 2018. PMID: 29168596 Free PMC article. Review.
Oral diverticulum.
Kadoya K, Ibaragi S, Tokunaga E, Kono T, Okui T, Sasaki A. Kadoya K, et al. Among authors: tokunaga e. J Gen Fam Med. 2018 Sep 19;19(6):221-222. doi: 10.1002/jgf2.205. eCollection 2018 Nov. J Gen Fam Med. 2018. PMID: 30464872 Free PMC article.
LAT1 expression influences Paneth cell number and tumor development in ApcMin/+ mice.
Sui Y, Hoshi N, Ohgaki R, Kong L, Yoshida R, Okamoto N, Kinoshita M, Miyazaki H, Ku Y, Tokunaga E, Ito Y, Watanabe D, Ooi M, Shinohara M, Sasaki K, Zen Y, Kotani T, Matozaki T, Tian Z, Kanai Y, Kodama Y. Sui Y, et al. Among authors: tokunaga e. J Gastroenterol. 2023 May;58(5):444-457. doi: 10.1007/s00535-023-01960-5. Epub 2023 Feb 5. J Gastroenterol. 2023. PMID: 36739585 Free PMC article.
Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
Shimomura A, Takano T, Takahashi S, Sagara Y, Watanabe J, Tokunaga E, Shinkai T, Kamio T, Kikumori K, Kamiyama E, Fujisaki Y, Saotome D, Yamashita T. Shimomura A, et al. Among authors: tokunaga e. Clin Pharmacol Ther. 2023 Jan;113(1):160-169. doi: 10.1002/cpt.2757. Epub 2022 Oct 18. Clin Pharmacol Ther. 2023. PMID: 36164935 Free PMC article.
341 results